Advances in oral macromolecular drug delivery

Expert Opinion on Drug Delivery

Volumn 11, Issue 12, 2014, Pages 1955-1967

  Hwang, Seung Rim ^a   Byun, Youngro ^b  

^a Chosun University   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Absorption enhancer; Chemical conjugation; Macromolecular drug; Oral delivery; Particle

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; DNA; EXENDIN 4; GASTRIN; GLUCAGON LIKE PEPTIDE 1; GROWTH HORMONE; HEPARIN; INSULIN; NANOPARTICLE; OCTREOTIDE; PACLITAXEL; MACROMOLECULE;

CELL TRANSPORT; CLINICAL TRIAL (TOPIC); CONJUGATION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG MECHANISM; HUMAN; INTESTINE ABSORPTION; MACROMOLECULE; NONHUMAN; ORAL DRUG ADMINISTRATION; PHYSICAL CHEMISTRY; REVIEW; ANIMAL; BIOAVAILABILITY; PHARMACOKINETICS; THERAPEUTIC USE;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; HUMANS; INTESTINAL ABSORPTION; MACROMOLECULAR SUBSTANCES;

EID: 84911467916     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2014.945420     Document Type: Review

References (105)

1. Willmann S, Schmitt W, Keldenich J, et al. A physiological model for the estimation of the fraction dose absorbed in humans. J Med Chem 2004;47(16):4022-31
2. Smith PL, Wall DA, Gochoco CH, Wilson G. (D) Routes of delivery: case studies:(5) Oral absorption of peptides and proteins. Adv Drug Deliv Rev 1992;8(2):253-90
3. Artursson P, Ungell AL, Lofroth JE. Selective paracellular permeability in two models of intestinal absorption: cultured monolayers of human intestinal epithelial cells and rat intestinal segments. Pharm Res 1993;10(8):1123-9
4. Donovan MD, Flynn GL, Amidon GL. Absorption of polyethylene glycols 600 through 2000: the molecular weight dependence of gastrointestinal and nasal absorption. Pharm Res 1990;7(8):863-8
5. Camenisch G, Alsenz J, van de Waterbeemd H, Folkers G. Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs' lipophilicity and molecular weight. Eur J Pharm Sci 1998;6(4):317-24
6. Woodley JF. Enzymatic barriers for GI peptide and protein delivery. Crit Rev Ther Drug Carrier Syst 1994;11(2-3):61-95
7. Chen MC, Sonaje K, Chen KJ, Sung HW. A review of the prospects for polymeric nanoparticle platforms in oral insulin delivery. Biomaterials 2011;32(36):9826-38
8. Fix JA. Oral controlled release technology for peptides: status and future prospects. Pharm Res 1996;13(12):1760-4
9. Renukuntla J, Vadlapudi AD, Patel A, et al. Approaches for enhancing oral bioavailability of peptides and proteins. Int J Pharm 2013;447(1):75-93
10. Salama NN, Eddington ND, Fasano A. Tight junction modulation and its relationship to drug delivery. Adv Drug Deliv Rev 2006;58(1):15-28
11. Madara JL. Regulation of the movement of solutes across tight junctions. Annu Rev Physiol 1998;60:143-59
12. Banan A, Zhang LJ, Shaikh M, et al. theta Isoform of protein kinase C alters barrier function in intestinal epithelium through modulation of distinct claudin isotypes: a novel mechanism for regulation of permeability. J Pharmacol Exp Ther 2005;313(3):962-82
13. Tsukita S, Furuse M, Itoh M. Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol 2001;2(4):285-93
14. Barry PH. Ionic permeation mechanisms in epithelia: biionic potentials, dilution potentials, conductances, and streaming potentials. Methods Enzymol 1989;171:678-715
15. Powell DW. Barrier function of epithelia. Am J Physiol 1981;241(4):G275-88
16. Shakweh M, Ponchel G, Fattal E. Particle uptake by Peyer's patches: a pathway for drug and vaccine delivery. Expert Opin Drug Deliv 2004;1(1):141-63
17. Cheng H, Leblond CP. Origin, differentiation and renewal of the four main epithelial cell types in the mouse small intestine. I. Columnar cell. Am J Anat 1974;141(4):461-79
18. Gebert A, Rothkotter HJ, Pabst R. M cells in Peyer's patches of the intestine. Int Rev Cytol 1996;167:91-159
19. Bai JP, Amidon GL. Structural specificity of mucosal-cell transport and metabolism of peptide drugs: implication for oral peptide drug delivery. Pharm Res 1992;9(8):969-78
20. Russell-Jones GJ. The potential use of receptor-mediated endocytosis for oral drug delivery. Adv Drug Deliv Rev 2001;46(1-3):59-73
21. Swaan PW. Recent advances in intestinal macromolecular drug delivery via receptor-mediated transport pathways. Pharm Res 1998;15(6):826-34
22. Shah D, Shen WC. Transcellular delivery of an insulin-transferrin conjugate in enterocyte-like Caco-2 cells. J Pharm Sci 1996;85(12):1306-11
23. Oh DM, Han HK, Amidon GL. Drug transport and targeting. Intestinal transport. Pharm Biotechnol 1999;12:59-88
24. Swaan PW, Hillgren KM, Szoka FC Jr, Oie S. Enhanced transepithelial transport of peptides by conjugation to cholic acid. Bioconjug Chem 1997;8(4):520-5
25. Russell-Jones GJ, Westwood SW, Habberfield AD. Vitamin B12 mediated oral delivery systems for granulocytecolony stimulating factor and erythropoietin. Bioconjug Chem 1995;6(4):459-65
26. Russell-Jones GJ. Use of vitamin B12 conjugates to deliver protein drugs by the oral route. Crit Rev Ther Drug Carrier Syst 1998;15(6):557-86
27. Lee Y, Nam JH, Shin HC, Byun Y. Conjugation of low-molecular-weight heparin and deoxycholic acid for the development of a new oral anticoagulant agent. Circulation 2001;104(25):3116-20
28. Lee YK, Kim SK, Lee DY, et al. Efficacy of orally active chemical conjugate of low molecular weight heparin and deoxycholic acid in rats, mice and monkeys. J Control Release 2006;111(3):290-8
29. Park JW, Jeon OC, Kim SK, et al. Anticoagulant efficacy of solid oral formulations containing a new heparin derivative. Mol Pharm 2010;7(3):836-43
30. Al-Hilal TA, Park J, Alam F, et al. Oligomeric bile acid-mediated oral delivery of low molecular weight heparin. J Control Release 2014;175:17-24
31. Meier PJ, Stieger B. Bile salt transporters. Annu Rev Physiol 2002;64:635-61
32. Lazaridis KN, Pham L, Tietz P, et al. Rat cholangiocytes absorb bile acids at their apical domain via the ileal sodium-dependent bile acid transporter. J Clin Invest 1997;100(11):2714-21
33. Al-Hilal TA, Chung SW, Alam F, et al. Functional transformations of bile acid transporters induced by high-affinity macromolecules. Sci Rep 2014;4:4163
34. Wu Y, Boysun MJ, Csencsits KL, Pascual DW. Gene transfer facilitated by a cellular targeting molecule, reovirus protein sigma1. Gene Ther 2000;7(1):61-9
35. Petrus AK, Vortherms AR, Fairchild TJ, Doyle RP. Vitamin B12 as a carrier for the oral delivery of insulin. ChemMedChem 2007;2(12):1717-21
36. Khafagy E-S, Morishita M. Oral biodrug delivery using cell-penetrating peptide. Adv Drug Deliv Rev 2012;64(6):531-9
37. Kamei N, Morishita M, Takayama K. Importance of intermolecular interaction on the improvement of intestinal therapeutic peptide/protein absorption using cell-penetrating peptides. J Control Release 2009;136(3):179-86
38. Foged C, Nielsen HM. Cell-penetrating peptides for drug delivery across membrane barriers. Expert Opin Drug Deliv 2008;5(1):105-17
39. Liang JF, Yang VC. Insulin-cell penetrating peptide hybrids with improved intestinal absorption efficiency. Biochem Biophys Res Commun 2005;335(3):734-8
40. Lee E, Lee J, Lee IH, et al. Conjugated chitosan as a novel platform for oral delivery of paclitaxel. J Med Chem 2008;51(20):6442-9
41. Lee E, Kim H, Lee IH, Jon S. In vivo antitumor effects of chitosan-conjugated docetaxel after oral administration. J Control Release 2009;140(2):79-85
42. Amidi M, Mastrobattista E, Jiskoot W, Hennink WE. Chitosan-based delivery systems for protein therapeutics and antigens. Adv Drug Deliv Rev 2010;62(1):59-82
43. Bonferoni MC, Sandri G, Rossi S, et al. Chitosan and its salts for mucosal and transmucosal delivery. Expert Opin Drug Deliv 2009;6(9):923-39
44. Werle M, Takeuchi H, Bernkop-Schnurch A. Modified chitosans for oral drug delivery. J Pharm Sci 2009;98(5):1643-56
45. Clement S, Still JG, Kosutic G, McAllister RG. Oral insulin product hexyl-insulin monoconjugate 2 (HIM2) in type 1 diabetes mellitus: the glucose stabilization effects of HIM2. Diabetes Technol Ther 2002;4(4):459-66
46. Wajcberg E, Miyazaki Y, Triplitt C, et al. Dose-response effect of a single administration of oral hexyl-insulin monoconjugate 2 in healthy nondiabetic subjects. Diabetes Care 2004;27(12):2868-73
47. Miller MA, Malkar NB, Severynse-Stevens D, et al. Amphiphilic conjugates of human brain natriuretic peptide designed for oral delivery: in vitro activity screening. Bioconjug Chem 2006;17(2):267-74
48. Cataliotti A, Chen HH, Schirger JA, et al. Chronic actions of a novel oral B-type natriuretic peptide conjugate in normal dogs and acute actions in angiotensin II-mediated hypertension. Circulation 2008;118(17):1729-36
49. Cataliotti A, Schirger JA, Martin FL, et al. Oral human brain natriuretic peptide activates cyclic guanosine 3′,5′-monophosphate and decreases mean arterial pressure. Circulation 2005;112(6):836-40
50. Chapman AP. PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev 2002;54(4):531-45
51. Asada H, Douen T, Waki M, et al. Absorption characteristics of chemically modified-insulin derivatives with various fatty acids in the small and large intestine. J Pharm Sci 1995;84(6):682-7
52. Hashizume M, Douen T, Murakami M, et al. Improvement of large intestinal absorption of insulin by chemical modification with palmitic acid in rats. J Pharm Pharmacol 1992;44(7):555-9
53. Yodoya E, Uemura K, Tenma T, et al. Enhanced permeability of tetragastrin across the rat intestinal membrane and its reduced degradation by acylation with various fatty acids. J Pharmacol Exp Ther 1994;271(3):1509-13
54. Morishita M, Morishita I, Takayama K, et al. Site-dependent effect of aprotinin, sodium caprate, Na2EDTA and sodium glycocholate on intestinal absorption of insulin. Biol Pharm Bull 1993;16(1):68-72
55. Thanou M, Verhoef JC, Junginger HE. Oral drug absorption enhancement by chitosan and its derivatives. Adv Drug Deliv Rev 2001;52(2):117-26
56. Rama Prasad YV, Minamimoto T, Yoshikawa Y, et al. In situ intestinal absorption studies on low molecular weight heparin in rats using labrasol as absorption enhancer. Int J Pharm 2004;271(1-2):225-32
57. Bernkop-Schnurch A, Hoffer MH, Kafedjiiski K. Thiomers for oral delivery of hydrophilic macromolecular drugs. Expert Opin Drug Deliv 2004;1(1):87-98
58. Scott Swenson E, Curatolo WJ. (C) Means to enhance penetration:(2) Intestinal permeability enhancement for proteins, peptides and other polar drugs: mechanisms and potential toxicity. Adv Drug Deliv Rev 1992;8(1):39-92
59. MS I S, Derle ND, Bhamber R. Permeability enhancement techniques for poorly permeable drugs: a review. J Appl Pharm Sci 2012;2(7):1-6
60. Mesiha MS, Ponnapula S, Plakogiannis F. Oral absorption of insulin encapsulated in artificial chyles of bile salts, palmitic acid and alphatocopherol dispersions. Int J Pharm 2002;249(1-2):1-5
61. O'Reilly JR, Corrigan OI, O'Driscoll CM. The effect of mixed micellar systems, bile salt/fatty acids, on the solubility and intestinal absorption of clofazimine (B663) in the anaesthetised rat. Int J Pharm 1994;109(2):147-54
62. Dawson PA, Lan T, Rao A. Bile acid transporters. J Lipid Res 2009;50(12):2340-57
63. Balakrishnan A, Polli JE. Apical sodium dependent bile acid transporter (ASBT, SLC10A2): a potential prodrug target. Mol Pharm 2006;3(3):223-30
64. Lee S, Lee J, Lee DY, et al. A new drug carrier, Nalpha-deoxycholyl-L: -lysylmethylester, for enhancing insulin absorption in the intestine. Diabetologia 2005;48(3):405-11
65. Lee DY, Lee J, Lee S, et al. Liphophilic complexation of heparin based on bile acid for oral delivery. J Control Release 2007;123(1):39-45
66. Motlekar NA, Srivenugopal KS, Wachtel MS, Youan B-BC. Oral delivery of low-molecular-weight heparin using sodium caprate as absorption enhancer reaches therapeutic levels. J Drug Target 2005;13(10):573-83
67. Thanou M, Nihot M, Jansen M, et al. Mono-N-carboxymethyl chitosan (MCC), a polyampholytic chitosan derivative, enhances the intestinal absorption of low molecular weight heparin across intestinal epithelia in vitro and in vivo. J Pharm Sci 2001;90(1):38-46
68. Thanou M, Henderson S, Kydonieus A, Elson C. N-sulfonato-N,O-carboxymethylchitosan: A novel polymeric absorption enhancer for the oral delivery of macromolecules. J Control Release 2007;117(2):171-8
69. Bernkop-Schnurch A, Kast CE, Guggi D. Permeation enhancing polymers in oral delivery of hydrophilic macromolecules: thiomer/GSH systems. J Control Release 2003;93(2):95-103
70. Croyle MA, Roessler BJ, Hsu CP, et al. Beta cyclodextrins enhance adenoviral-mediated gene delivery to the intestine. Pharm Res 1998;15(9):1348-55
71. Maher S, Leonard TW, Jacobsen J, Brayden DJ. Safety and efficacy of sodium caprate in promoting oral drug absorption: from in vitro to the clinic. Adv Drug Deliv Rev 2009;61(15):1427-49
72. Arbit E, Kidron M. Oral insulin: the rationale for this approach and current developments. J Diabetes Sci Technol 2009;3(3):562-7
73. Werle M, Makhlof A, Takeuchi H. Oral protein delivery: a patent review of academic and industrial approaches. Recent Pat Drug Deliv Formul 2009;3(2):94-104
74. Park K, Kwon IC, Park K. Oral protein delivery: current status and future prospect. React Funct Polym 2011;71(3):280-7
75. Steinert RE, Poller B, Castelli MC, et al. Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects. Am J Clin Nutr 2010;92(4):810-17
76. McGavigan AK, Murphy KG. Gut hormones: the future of obesity treatment? Br J Clin Pharmacol 2012;74(6):911-19
77. Bauer W, Briner U, Doepfner W, et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982;31(11):1133-40
78. Tuvia S, Atsmon J, Teichman SL, et al. Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. J Clin Endocrinol Metab 2012;97(7):2362-9
79. Cano-Cebrian MJ, Zornoza T, Granero L, Polache A. Intestinal absorption enhancement via the paracellular route by fatty acids, chitosans and others: a target for drug delivery. Curr Drug Deliv 2005;2(1):9-22
80. Grasso LF, Pivonello R, Colao A. Investigational therapies for acromegaly. Expert Opin Investig Drugs 2013;22(8):955-63
81. Damge C, Michel C, Aprahamian M, Couvreur P. New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carrier. Diabetes 1988;37(2):246-51
82. Jepson MA, Simmons NL, O'Hagan DT, Hirst BH. Comparison of poly(DL-lactide-co-glycolide) and polystyrene microsphere targeting to intestinal M cells. J Drug Target 1993;1(3):245-9
83. Carino GP, Jacob JS, Mathiowitz E. Nanosphere based oral insulin delivery. J Control Release 2000;65(1-2):261-9
84. Desai MP, Labhasetwar V, Amidon GL, Levy RJ. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res 1996;13(12):1838-45
85. McClean S, Prosser E, Meehan E, et al. Binding and uptake of biodegradable poly-DL-lactide micro- and nanoparticles in intestinal epithelia. Eur J Pharm Sci 1998;6(2):153-63
86. Jung T, Kamm W, Breitenbach A, et al. Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake? Eur J Pharm Biopharm 2000;50(1):147-60
87. Sonaje K, Chen YJ, Chen HL, et al. Enteric-coated capsules filled with freeze-dried chitosan/poly(gammaglutamic acid) nanoparticles for oral insulin delivery. Biomaterials 2010;31(12):3384-94
88. Sonaje K, Lin YH, Juang JH, et al. In vivo evaluation of safety and efficacy of self-assembled nanoparticles for oral insulin delivery. Biomaterials 2009;30(12):2329-39
89. Sonaje K, Lin KJ, Wey SP, et al. Biodistribution, pharmacodynamics and pharmacokinetics of insulin analogues in a rat model: oral delivery using pH-responsive nanoparticles vs. subcutaneous injection. Biomaterials 2010;31(26):6849-58
90. Nguyen HN, Wey SP, Juang JH, et al. The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo. Biomaterials 2011;32(10):2673-82
91. Sarmento B, Ribeiro A, Veiga F, et al. Oral bioavailability of insulin contained in polysaccharide nanoparticles. Biomacromolecules 2007;8(10):3054-60
92. Sarmento B, Ribeiro A, Veiga F, et al. Alginate/chitosan nanoparticles are effective for oral insulin delivery. Pharm Res 2007;24(12):2198-206
93. Behrens I, Pena AI, Alonso MJ, Kissel T. Comparative uptake studies of bioadhesive and non-bioadhesive nanoparticles in human intestinal cell lines and rats: the effect of mucus on particle adsorption and transport. Pharm Res 2002;19(8):1185-93
94. des Rieux A, Fievez V, Garinot M, et al. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release 2006;116(1):1-27
95. Florence AT. The oral absorption of micro- and nanoparticulates: neither exceptional nor unusual. Pharm Res 1997;14(3):259-66
96. Geho WB, Geho HC, Lau JR, Gana TJ. Hepatic-directed vesicle insulin: a review of formulation development and preclinical evaluation. J Diabetes Sci Technol 2009;3(6):1451-9
97. Plapied L, Duhem N, des Rieux A, Preat V. Fate of polymeric nanocarriers for oral drug delivery. Curr Opin Colloid In 2011;16(3):228-37
98. Chalasani KB, Russell-Jones GJ, Jain AK, et al. Effective oral delivery of insulin in animal models using vitamin B12-coated dextran nanoparticles. J Control Release 2007;122(2):141-50
99. Zijlstra E, Heinemann L, Plum-Morschel L. Oral insulin reloaded: a structured approach. J Diabetes Sci Technol 2014;8(3):458-65
100. Sheridan C. Proof of concept for next-generation nanoparticle drugs in humans. Nat Biotechnol 2012;30(6):471-3
101. Jiao Y, Ubrich N, Marchand-Arvier M, et al. In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits. Circulation 2002;105(2):230-5
102. Shohet S, Wood G. Delivering biotherapeutics - technical opportunities and strategic trends. J Commercial Biotechnol 2002;9(1):59-66
103. Dekel Y, Glucksam Y, Mar galit R. Novel fibrillar insulin formulations for oral administration: formulation and in vivo studies in diabetic mice. J Control Release 2010;143(1):128-35
104. Sandri G, Rossi S, Ferrari F, et al. Mucoadhesive and penetration enhancement properties of three grades of hyaluronic acid using porcine buccal and vaginal tissue, Caco-2 cell lines, and rat jejunum. J Pharm Pharmacol 2004;56(9):1083-90
105. Lamprecht A, Ubrich N, Maincent P. Oral low molecular weight heparin delivery by microparticles from complex coacervation. Eur J Pharm Biopharm 2007;67(3):632-8